Charles River Laboratories Intl. Inc vs Southern Copper Corp — how do they compare? Charles River Laboratories Intl. Inc trades at $227.69 (market cap $11.14B), while Southern Copper Corp trades at $181.05 (market cap $152.16B). The key difference: Southern Copper Corp is far larger — about 13.7× Charles River Laboratories Intl. Inc's market cap, and Southern Copper Corp pays a 2.17% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| CRL | SCCO | |
|---|---|---|
Market Cap | $11.14B | $152.16B |
Sector | Health | Basic Materials |
52-Week High | $233.60 | $218.85 |
52-Week Low | $145.57 | $90.54 |
Enterprise Value | $14.00B | $154.22B |
Dividend Yield | — | 2.17% |
Signals from Pluang's Aura AI — not financial advice
Charles River Laboratories (CRL) trades at $229.75, down 1.57% on the day, near its consensus price target of $229.80. The stock shows a bullish technical trend with strong moving average signals and support at $225. Fundamentally, CRL has beaten EPS estimates for three consecutive quarters but reported a net loss of $144.34 million in 2025, with negative profit margins. Recent news highlights collaborations in AI and NGS services, supporting growth prospects.
Outlook remains mixed: analyst consensus is strongly bullish with 72% buy ratings and a high target of $260, but profitability challenges and high P/E of 684.85 pose risks. Cash flow stability and strategic partnerships offer upside, while margin pressures and debt levels require monitoring for sustained recovery.
Southern Copper (SCCO) trades at $174.53, down 0.74% on the day, with a bearish technical signal and mixed analyst sentiment. The stock shows strong fundamentals, including a 32.3% net income margin and consistent earnings beats, with Q1 2026 EPS of $1.90 exceeding the $1.82 estimate. Revenue grew to $13.42 billion in 2025, and cash flow from operations reached $4.75 billion. Recent corporate actions include a $1.00 dividend and a 1:1.01 stock split effective May 13, 2026.
The outlook for SCCO is supported by robust profitability and growth in the copper sector, driven by AI and infrastructure demand, but risks include high valuation multiples and bearish technical indicators. Analyst consensus is cautious with a $151.58 price target below the current price, indicating potential downside despite strong operational performance.
Trailing returns across standard periods
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Southern Copper Corp is an integrated producer of copper and other minerals and operates the mining, smelting, and refining facilities in Peru and Mexico. Its production includes copper, molybdenum, zinc, and silver. The company operates through the following segments: Peruvian operations, Mexican open-pit operations, and Mexican underground mining operations. Southern Copper generates the majority of its revenue from the sale of copper and the rest from the sale of non-copper products, such as molybdenum, silver, zinc, lead, and gold. Its geographical segments are The Americas, Europe, and Asia.
Read more on SCCO →